Recent Press Releases

Orexigen and Takeda File Lawsuit Against Actavis for Infringement of Contrave® Patents

SAN DIEGO, June 5, 2015 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that it and its North American partner, Takeda Pharmaceuticals, have filed a lawsuit in the U.S....

NICE publishes draft guidance for two prostate cancer treatments

NICE publishes draft guidance for two prostate cancer treatments The National Institute for Health and Care Excellence (NICE) has launched public consultations on draft recommendations for two...

Lilly commits 780,000 additional vials of insulin to Life for a Child

Renewed commitment will help more children in impoverished communities

INDIANAPOLIS, June 4, 2015 /P

Lilly to Present Pivotal Phase 3 Study Results for Investigational Psoriasis Treatment at 23rd World Congress of Dermatology

INDIANAPOLIS, June 4, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will showcase results from three

Universal Health Services, Inc. To Present At Goldman Sachs 36th Annual Global Healthcare Conference

KING OF PRUSSIA, Pa., June 3, 2015 /PRNewswire/ -- Universal Health Services, Inc.

Roche receives FDA clearance for the cobas® HSV 1 and 2 Test for the detection of herpes simplex virus

New test expands menu for sexually transmitted infections testing on the cobas® 4800 System

PLEASANTON, Calif.,

Ardelyx Regains Worldwide Development and Commercialization Rights for Its Late-Stage Development Candidate, Tenapanor, and Related Portfolio of NHE3 Compounds

Ardelyx to Initiate a Phase 3 Clinical Program in IBS-C Patients in the Fourth Quarter of 2015

FREMONT, Calif.,

Endo International plc Announces Proposed Public Offering of $1.75 Billion of Ordinary Shares

Endo International plc Announces Proposed Public Offering of $1.75 Billion of Ordinary Shares DUBLIN, June 2, 2015 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) (the...

Endo International plc Announces Proposed Public Offering of $1.75 Billion of Ordinary Shares

DUBLIN, June 2, 2015 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) (the "Company" or "Endo") announced today that it has commenced an underwritten public...

Actavis Affirms Commitment To Advancing Antibiotic Stewardship At White House Forum

- Actavis Commitment Extends to Fostering Collaborative Research Efforts, Gathering Unique Epidemiological Information and Generating Real-World Data to Demonstrate the Effects of Stewardship on P

POZEN Announces Retirement of Founder, Chairman and CEO Dr. John R. Plachetka; Adrian Adams Named as CEO

CHAPEL HILL, N.C.--POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to developing medicine that transforms lives, today announced that John R. Plachetka, Pharm.D., its founder, Chairman,...

Perrigo To Acquire Portfolio Of Leading OTC Brands From GSK

-- Portfolio includes well-established European brands in the areas of nicotine replacement therapy, cold and flu, and cold sore management -- Demonstrates Perrigo's unique ability to maximize...

Actavis And Perrigo Receive FDA Approval Of Guaifenesin/Pseudoephedrine, The Store Brand Equivalent To Mucinex(R) D Tablets

DUBLIN, June 2, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) and its partner Perrigo Company plc (NYSE: PRGO; TASE) announced today that Actavis has received U.S. Food and Drug Administration...

POZEN Announces Retirement Of Founder, Chairman And CEO Dr. John R. Plachetka; Adrian Adams Named As CEO

POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to developing medicine that transforms lives, today announced that John R. Plachetka, Pharm.D., its founder, Chairman, Chief Executive...

Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab

First Trial to Combine These Investigational Immunotherapies for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

Amgen Initiates Phase 3 Study Evaluating Once-Weekly Kyprolis® (carfilzomib) in Patients With Relapsed And Refractory Multiple Myeloma

Data from Once-Weekly CHAMPION Phase 1/2 Study Presented at ASCO

THOUSAND OAKS, Calif., May 31, 2015

Combination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic melanoma

-- Final analysis of COMBI-d confirms overall survival benefit of combination therapy in patients with BRAF V600E/K mutation-positive metastatic melanoma -- Tafinlar and Mekinist in combination...

Actavis Completes Acquisition of Auden Mckenzie

DUBLIN, June 1, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has completed its acquisition of Auden Mckenzie Holdings Limited, a dynamic and fast growing company focused on...

GENENTECH'S PERJETA REGIMEN HELPED PEOPLE WITH HER2-POSITIVE EARLY BREAST CANCER LIVE LONGER WITHOUT THEIR DISEASE RETURNING OR GETTING WORSE COMPARED TO HERCEPTIN AND CHEMOTHERAPY

-- New data from Phase II NeoSphere study provide additional evidence on the role of Perjeta in the neoadjuvant (pre-surgery) treatment of HER2-positive early breast cancer -- Chicago – June...